蓝光滤过型人工晶状体对新生血管性年龄相关性黄斑变性发生与进展的影响
结果显示两组无nAMD生存率相似(P=0.465),BLF人工晶状体并非nAMD发生的预测因素(HR 1.075;95%CI 0.79-1.47;P=0.652),在术前已存在nAMD的患者中一年临床结局亦相当。
要点
- BLF人工晶状体未降低白内障术后nAMD发生率(HR 1.075;95%CI 0.79-1.47;P=0.652)。
- 两组无nAMD生存率相似(P=0.465,log-rank检验)。
- 术前已存在nAMD者,BLF与非BLF人工晶状体一年临床结局相当(均P>0.05)。
核心结论
- 在白内障手术患者中,BLF人工晶状体在nAMD发生率或进展方面未见优于非BLF人工晶状体。
- BLF人工晶状体亦未改善与nAMD严重程度相关的临床变量。
研究设计与样本
- 队列研究,纳入2007至2018年在芬兰Kymenlaakso中心医院眼科接受顺利白内障手术的患者。
- BLF人工晶状体组5425眼(47.6%),非BLF人工晶状体组5972眼(52.4%)。
- 随访时间:BLF组55.2±34.1个月,非BLF组50.5±30.1个月(P<0.001)。
- 每例患者仅纳入一只眼。
主要发现
- 随访期间共记录164例新发nAMD(BLF组88例,非BLF组76例)。
- 两组无nAMD生存率相似(P=0.465,log-rank检验)。
- 控制年龄、性别及已诊断黄斑变性后,BLF人工晶状体并非nAMD发生的预测因素(HR 1.075;95%CI 0.79-1.47;P=0.652)。
- 在术前已存在nAMD的患者中(BLF组71例,非BLF组74例),一年临床结局相当(均P>0.05)。
关键数值与推荐
- 主要结局为无nAMD生存。
- 在nAMD患者中,BLF组与非BLF组一年最佳矫正视力分别为0.57±0.4 logMAR与0.45±0.4 logMAR(P=0.136)。
- 在nAMD患者中,BLF组与非BLF组黄斑中心凹厚度分别为285±109 μm与299±103 μm(P=0.527)。
- 在nAMD患者中,BLF组与非BLF组抗血管内皮生长因子注射次数分别为6.5±2.5次与6.2±2.7次(P=0.548)。
- 在nAMD患者中,BLF组与非BLF组治疗间隔分别为7.5±2.4周与8.1±2.4周(P=0.271)。
临床怎么用
- BLF人工晶状体不应以预防nAMD发生或延缓进展为主要目的进行选择。
- 对于术前已存在nAMD的患者,BLF人工晶状体未显示影响一年视力、黄斑厚度或抗VEGF治疗需求。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the effect of blue-light filtering (BLF) intraocular lenses (IOLs) on the prevention of neovascular age-related macular degeneration (nAMD) after cataract surgery. DESIGN: Cohort study. PARTICIPANTS: Patients who underwent uneventful cataract surgery between 2007 and 2018 at the Ophthalmology Unit of Kymenlaakso Central Hospital, Kotka, Finland. METHODS: Subsequent nAMD rates were compared between patients who received BLF IOLs and those who received non-BLF IOLs. Kaplan-Meier and Cox regression analyses for the overall risk of nAMD developing were assessed. Best-corrected visual acuity (BCVA), foveal thickness, treatment interval, and total number of intravitreal injections were secondary outcomes. A separate analysis was performed on patients with pre-existing nAMD to assess the effect of BLF IOLs on nAMD progression. A single eye of each patient was included. MAIN OUTCOME MEASURE: Neovascular age-related macular degeneration-free survival. RESULTS: Included were 11 397 eyes of 11 397 patients with a mean age of 75.4 ± 8.3 years (62.5% women). The BLF IOL was used in 5425 eyes (47.6%), and the non-BLF IOL was used in 5972 eyes (52.4%). During follow-up (BLF IOL group, 55.2 ± 34.1 months; non-BLF IOL group, 50.5 ± 30.1 months; P < 0.001), 164 cases of new-onset nAMD were recorded (BLF group, n = 88; non-BLF group, n = 76). The nAMD-free survival was similar between the groups (P = 0.465, log-rank test). In a Cox regression analysis controlling for age, gender, and a documented diagnosis of macular degeneration, the use of a BLF IOL was not predictive of nAMD development (hazard ratio [HR], 1.075; 95% confidence interval [CI], 0.79-1.47; P = 0.652). In nAMD patients, secondary clinical outcomes at 1 year were comparable for BCVA (0.57 ± 0.4 logarithm of the minimum angle of resolution vs. 0.45 ± 0.4 logarithm of the minimum angle of resolution; P = 0.136), foveal thickness (285 ± 109 μm vs. 299 ± 103μm; P = 0.527), number of anti-vascular endothelial growth factor injections (6.5 ± 2.5 vs. 6.2 ± 2.7; P = 0.548), and treatment interval (7.5 ± 2.4 weeks vs. 8.1 ± 2.4 weeks; P = 0.271) for BLF and non-BLF IOLs, respectively. Similarly to patients in whom nAMD developed after the surgery, among patients with nAMD before surgery (BLF, n = 71; non-BLF, n = 74), the clinical outcomes again were comparable (all P > 0.05). CONCLUSIONS: In a large cohort of patients who underwent cataract surgery, the use of a BLF IOL resulted in no apparent advantage over a non-BLF IOL in the incidence of nAMD or its progression, nor in clinical variables related to nAMD severity.
引用
- Achiron A, Elbaz U, Hecht I, et al. The Effect of Blue-Light Filtering Intraocular Lenses on the Development and Progression of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020. PMID: 32717342. doi:10.1016/j.ophtha.2020.07.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。